作者
James J Harding, Subhiksha Nandakumar, Joshua Armenia, Danny N Khalil, Melanie Albano, Michele Ly, Jinru Shia, Jaclyn F Hechtman, Ritika Kundra, Imane El Dika, Richard K Do, Yichao Sun, T Peter Kingham, Michael I D'Angelica, Michael F Berger, David M Hyman, William Jarnagin, David S Klimstra, Yelena Y Janjigian, David B Solit, Nikolaus Schultz, Ghassan K Abou-Alfa
发表日期
2019/4/1
期刊
Clinical Cancer Research
卷号
25
期号
7
页码范围
2116-2126
出版商
American Association for Cancer Research
简介
Purpose
Prior molecular profiling of hepatocellular carcinoma (HCC) has identified actionable findings that may have a role in guiding therapeutic decision-making and clinical trial enrollment. We implemented prospective next-generation sequencing (NGS) in the clinic to determine whether such analyses provide predictive and/or prognostic information for HCC patients treated with contemporary systemic therapies.
Experimental Design
Matched tumor/normal DNA from patients with HCC (N = 127) were analyzed using a hybridization capture–based NGS assay designed to target 341 or more cancer-associated genes. Demographic and treatment data were prospectively collected with the goal of correlating treatment outcomes and drug response with molecular profiles.
Results
WNT/β-catenin pathway (45%) and TP53 (33%) alterations were frequent and …
学术搜索中的文章
JJ Harding, S Nandakumar, J Armenia, DN Khalil… - Clinical Cancer Research, 2019